- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 10.10. | Evommune files for IPO to advance immune drug work | ||
| 09.10. | Novo joins MASH dealmaking surge with $4.7B Akero buyout | ||
| 09.10. | Regeneron, needing a turnaround, gains new use for cancer drug | ||
| 08.10. | Arthrosi snags $153M in pursuit of a new gout drug | ||
| 08.10. | Venture firms pour $101M into a biotech using the brain to fix the immune system | ||
| 08.10. | Zenas looks to China to stock pipeline with 3 more immune drugs | ||
| 08.10. | Boehringer Ingelheim drug wins FDA OK in tough-to-treat lung disease | ||
| 07.10. | Peter Marks, former top FDA vaccine official, joins Eli Lilly | ||
| 07.10. | MapLight uses workaround to tee up IPO during government shutdown | ||
| 07.10. | Lexeo says FDA open to speedier approval of rare disease gene therapy | ||
| 06.10. | AstraZeneca, Daiichi drug extends survival in hard-to-treat breast cancer | ||
| 06.10. | Skye shares crash as obesity drug falls short in key study | ||
| 06.10. | Chiesi buys into Arbor gene editing drug for rare kidney disease | ||
| 06.10. | The advantage of engaging patient recruitment partners as strategic allies, not emergency backups | ||
| 06.10. | Immune reset: How T cell engagers can change the autoimmune treatment landscape | ||
| 03.10. | AI could transform healthcare. Can safety-net providers keep up? | ||
| 03.10. | FDA clears generic abortion pill; CMS punts 'combo drug' guidance | ||
| 02.10. | Amgen claims 'landmark' study result that could widen heart drug's use | ||
| 02.10. | Galapagos to decide on fate of cell therapy business 'within weeks' | ||
| 02.10. | Cartography secures $67M in pursuit of 'differentiated' cancer drugs | ||
| 01.10. | Takeda, in reversal, abandons cell therapy research | ||
| 01.10. | The top biopharma conferences in 2026 | ||
| 01.10. | A new biotech aims to get RNA drugs into the brain | ||
| 01.10. | As shutdown begins, FDA to stop accepting new drug submissions | ||
| 01.10. | FDA official's comments spark Aurinia sell-off; Halozyme buys a biotech |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .